fbpx

Gene Therapy for Age-related Macular Degeneration Pipeline Analysis Report 2018 – ResearchAndMarkets.com

The “Gene
Therapy for Age-related Macular Degeneration – A Pipeline Analysis
Report” report has been added to ResearchAndMarkets.com’s
offering.

This pipeline analysis report provides detailed insights into the
clinical trials landscape of the gene therapy molecules for age-related
macular degeneration in the development and pre-clinical stages. The
report also offers comprehensive information about the therapeutic
assessment of the pipeline molecules based on various segmentations such
as therapy, route of administration, and target.

Overview of the gene therapy pipeline for age-related macular
degeneration

It has been observed that age-related macular degeneration (AMD) is one
of the major causes for vision loss and is characterized by the
formation of a blurred area near the center of vision, a condition that
mostly affects the geriatric population. According to the CDC, almost 2
million individuals in the US suffer from AMD and by 2050, this number
will reach more than 5 million. This will subsequently demand the need
for the development of innovative treatments for AMD, driving the
market’s growth.

The market research analysts have predicted that with the introduction
of techniques such as fluorescein angiography, the global age-related
macular degeneration market will register a CAGR of more than 7% by
2020. With the unavailability of FDA-approved treatment for dry AMD
(dAMD) and the treatment of wet AMD (wAMD) involving the need of
intravitreal injections for an indefinite period, gene therapy is
emerging as the most-efficient approach for the treatment of age-related
macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy
molecules in the pipeline are being developed for wet AMD (wAMD). Our
market research analysts have also identified that most of these
molecules are in the pre-clinical development stage and a considerable
number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the
companies that are involved in the development of gene therapy molecules
for the treatment of AMD. In addition to providing information on the
various stages of molecules developed by companies for different
indications, this pipeline analysis report also provides information
about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report
are

Therapeutic assessment of the gene therapy pipeline for AMD by
route of administration

The intravitreal route of administration (ROA) involves the application
of the drug directly onto the vitreous fluid and in the subretinal
technique, the molecules are applied to the subretinal space, which will
have a more direct effect on the target cells.

Therapeutic assessment of the gene therapy pipeline for AMD by
therapy

According to this pipeline analysis report, all the molecules that are
currently in the gene therapy pipeline for age-related macular
degeneration are being developed as monotherapy drugs and most of these
molecules are in the pre-clinical stage of development.

Key questions answered in the report include

For more information about this report visit https://www.researchandmarkets.com/research/93p585/gene_therapy_for?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005321/en/